ma

Pathways to Quality Inpatient Management of Hyperglycemia and Diabetes: A Call to Action

Boris Draznin
Jul 1, 2013; 36:1807-1814
Perspectives in Care




ma

Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections from a Diabetes Care Editors' Expert Forum

Itamar Raz
Jun 1, 2013; 36:1779-1788
Diabetes Care Expert Forum




ma

Manufactured Shoes in the Prevention of Diabetic Foot Ulcers

Luigi Uccioli
Oct 1, 1995; 18:1376-1378
Short Report




ma

A Mathematical Model for the Determination of Total Area Under Glucose Tolerance and Other Metabolic Curves

Mary M Tai
Feb 1, 1994; 17:152-154
Short Report




ma

Increased Carotid Intima-Media Thickness and Stiffness in Obese Children

Arcangelo Iannuzzi
Oct 1, 2004; 27:2506-2508
Brief Reports




ma

Acute Effects of Insulin in the Control of VLDL Production in Humans: Implications for the insulin-resistant state

Gary F Lewis
Apr 1, 1996; 19:390-393
Symposium On Insulin Resistance




ma

Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes

Tina Vilsbøll
Jun 1, 2007; 30:1608-1610
BR Emerging Treatments and Technologies




ma

Diabetes and Obesity in the Offspring of Pima Indian Women With Diabetes During Pregnancy

David J Pettitt
Jan 1, 1993; 16:310-314
Supplement 1: Diabetes in Native Americans




ma

Relationship Between {beta}-Cell Mass and Fasting Blood Glucose Concentration in Humans

Robert A. Ritzel
Mar 1, 2006; 29:717-718
BR Pathophysiology/Complications




ma

Diabetes Prevention in the Real World: Effectiveness of Pragmatic Lifestyle Interventions for the Prevention of Type 2 Diabetes and of the Impact of Adherence to Guideline Recommendations: A Systematic Review and Meta-analysis

Alison J. Dunkley
Apr 1, 2014; 37:922-933
Current Concepts of Type 2 Diabetes Prevention




ma

A Prospective Analysis of the HOMA Model: The Mexico City Diabetes Study

Steven M Haffner
Oct 1, 1996; 19:1138-1141
Short Report




ma

Relationship of Glucose Tolerance and Plasma Insulin to the Incidence of Coronary Heart Disease: Results from Two Population Studies in Finland

Kalevi Pyörälä
Mar 1, 1979; 2:131-141
Proceedings of the Kroc Foundation International Conference on Epidemiology of Diabetes and its Macrovascular Complications




ma

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association

Richard A. Insel
Oct 1, 2015; 38:1964-1974
Scientific Statement




ma

Hyperglycemie and Microvascular and Macrovascular Disease in Diabetes

Ronald Klein
Feb 1, 1995; 18:258-268
Kelly West Lecture 1994




ma

India police: Security forces kill top militant commander in Kashmir

Police in India said security forces killed a top Hizbul Mujahideen commander amid a series of gunfights in the disputed Jammu and Kashmir region on Wednesday.




ma

Ex-South Korea comfort woman accuses activist of exploiting women, funds

A former South Korean comfort woman accused an influential activist group of misappropriating funds and using past victims to advance their cause.




ma

Google-related company pulls plug on Toronto 'smart city' project

A Google-related company has pulled the plug on its ambitious high-tech waterfront city project in Toronto, citing financial strains from the coronavirus, but the project had also run into local opposition.




ma

Subdued ceremonies in Europe mark 75th anniversary of VE Day

French President Emanuel Macron led a series of events in Europe Friday that commemorate the 75th anniversary of Victory in Europe Day, with a small ceremony in Paris.




ma

Northrop Grumman awarded $123.5M to integrate Navy LAIRCM system

Northrop Grumman received a $123.5 million contract modification Friday to integrate the Department of Navy Large Aircraft Infrared Countermeasures system onto aircraft for the U.S. military and two allied governments.




ma

Northrop Grumman, Raytheon partner for Next Generation Interceptor bid

Northrop Grumman Corp. and Raytheon Missiles and Defense will partner to develop the Defense Department's next missile interceptor, they announced on Monday.




ma

Israel Defense Ministry buys small exploding drones

Israel's Ministry of Defense ordered small drones for its ground forces working in urban areas, maker Rafael Advanced Defense Systems Ltd. said Monday.




ma

Coast Guard names Rear Adm. Melissa Bert as first female judge advocate general

The U.S. Coast Guard named Rear Adm. Melissa Bert as its first female judge advocate and chief counsel, its top legal position.




ma

Boeing presents first Loyal Wingman drone aircraft to Australia

Boeing announced Tuesday has presented its first unmanned aircraft to the Royal Australian Air Force.




ma

Air Force, Marines train near China amid heightened tensions

The Air Force and Marines have both reported engaging in training maneuvers in the East and South China Sea in recent weeks amid escalating tensions in the region.




ma

Air Force sets May 16 launch for X-37B spy plane

The Air Force said Wednesday it will launch the sixth mission of the uncrewed X-37B spy plane May 16 from Florida with a record number of experiments on board.




ma

3M inks $126M deal with DoD to increase N95 mask production in October

3M has signed a $126 million deal with the Pentagon to increase its production of N95 masks to 26 million per month beginning in October 2020.




ma

Memo: Prior COVID-19 diagnosis 'permanently disqualifying' for U.S. military service

Military Entrance Processing Stations won't process individuals who have had COVID-19 for military service, even if they've fully recovered from the virus, the Pentagon confirmed this week.




ma

Gestational Diabetes Mellitus and Diet: A Systematic Review and Meta-analysis of Randomized Controlled Trials Examining the Impact of Modified Dietary Interventions on Maternal Glucose Control and Neonatal Birth Weight

Jennifer M. Yamamoto
Jul 1, 2018; 41:1346-1361
Reconsidering Pregnancy With Diabetes




ma

Investigation of the Accuracy of 18 Marketed Blood Glucose Monitors

David C. Klonoff
Aug 1, 2018; 41:1681-1688
Emerging Technologies: Data Systems and Devices




ma

Table 1--Systeme International (SI) units for plasma, serum, or blood concentrations


Apr 1, 1994; 17:360-361
Syst[egrave]me International (SI) Units




ma

Table 1--Systeme International (SI) units for plasma, serum, or blood concentrations


Nov 1, 1995; 18:1524-1525
Syst[egrave]me International (SI) Units




ma

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association

Richard A. Insel
Oct 1, 2015; 38:1964-1974
Scientific Statement




ma

PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes

Vanita R. Aroda
Sep 1, 2019; 42:1724-1732
Emerging Therapies: Drugs and Regimens




ma

Impact of Fat, Protein, and Glycemic Index on Postprandial Glucose Control in Type 1 Diabetes: Implications for Intensive Diabetes Management in the Continuous Glucose Monitoring Era

Kirstine J. Bell
Jun 1, 2015; 38:1008-1015
Type 1 Diabetes at a Crossroads




ma

Current Challenges and Opportunities in the Prevention and Management of Diabetic Foot Ulcers

William J. Jeffcoate
Apr 1, 2018; 41:645-652
Perspectives in Care




ma

Management of Inpatient Hyperglycemia and Diabetes in Older Adults

Guillermo E. Umpierrez
Apr 1, 2017; 40:509-517
Emerging Science and Concepts for Management of Diabetes and Aging




ma

Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring

Richard M. Bergenstal
Nov 1, 2018; 41:2275-2280
Perspectives in Care




ma

Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial

Helena W. Rodbard
Dec 1, 2019; 42:2272-2281
Emerging Therapies: Drugs and Regimens




ma

2017 National Standards for Diabetes Self-Management Education and Support

Joni Beck
Oct 1, 2017; 40:1409-1419
National Standards




ma

Table 1-Systeme International (SI) units for plasma, serum, or blood concentrations


Aug 1, 1995; 18:1223-1224
Syst[egrave]me International (SI) Units




ma

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

John B. Buse
Feb 1, 2020; 43:487-493
Consensus Report Update




ma

Vasodilatory Actions of Glucagon-Like Peptide 1 Are Preserved in Skeletal and Cardiac Muscle Microvasculature but Not in Conduit Artery in Obese Humans With Vascular Insulin Resistance

OBJECTIVE

Obesity is associated with microvascular insulin resistance, which is characterized by impaired insulin-mediated microvascular recruitment. Glucagon-like peptide 1 (GLP-1) recruits skeletal and cardiac muscle microvasculature, and this action is preserved in insulin-resistant rodents. We aimed to examine whether GLP-1 recruits microvasculature and improves the action of insulin in obese humans.

RESEARCH DESIGN AND METHODS

Fifteen obese adults received intravenous infusion of either saline or GLP-1 (1.2 pmol/kg/min) for 150 min with or without a euglycemic insulin clamp (1 mU/kg/min) superimposed over the last 120 min. Skeletal and cardiac muscle microvascular blood volume (MBV), flow velocity and blood flow, brachial artery diameter and blood flow, and pulse wave velocity (PWV) were determined.

RESULTS

Insulin failed to change MBV or flow in either skeletal or cardiac muscle, confirming the presence of microvascular insulin resistance. GLP-1 infusion alone increased MBV by ~30% and ~40% in skeletal and cardiac muscle, respectively, with no change in flow velocity, leading to a significant increase in microvascular blood flow in both skeletal and cardiac muscle. Superimposition of insulin to GLP-1 infusion did not further increase MBV or flow in either skeletal or cardiac muscle but raised the steady-state glucose infusion rate by ~20%. Insulin, GLP-1, and GLP-1 + insulin infusion did not alter brachial artery diameter and blood flow or PWV. The vasodilatory actions of GLP-1 are preserved in both skeletal and cardiac muscle microvasculature, which may contribute to improving metabolic insulin responses and cardiovascular outcomes.

CONCLUSIONS

In obese humans with microvascular insulin resistance, GLP-1’s vasodilatory actions are preserved in both skeletal and cardiac muscle microvasculature, which may contribute to improving metabolic insulin responses and cardiovascular outcomes.




ma

Time Course of Normalization of Functional {beta}-Cell Capacity in the Diabetes Remission Clinical Trial After Weight Loss in Type 2 Diabetes

OBJECTIVE

To assess functional β-cell capacity in type 2 diabetes during 2 years of remission induced by dietary weight loss.

RESEARCH DESIGN AND METHODS

A Stepped Insulin Secretion Test with Arginine was used to quantify functional β-cell capacity by hyperglycemia and arginine stimulation. Thirty-nine of 57 participants initially achieved remission (HbA1c <6.5% [<48 mmol/mol] and fasting plasma glucose <7 mmol/L on no antidiabetic drug therapy) with a 16.4 ± 7.7 kg weight loss and were followed up with supportive advice on avoidance of weight regain. At 2 years, 20 participants remained in remission in the study. A nondiabetic control (NDC) group, matched for age, sex, and weight after weight loss with the intervention group, was studied once.

RESULTS

During remission, median (interquartile range) maximal rate of insulin secretion increased from 581 (480–811) pmol/min/m2 at baseline to 736 (542–998) pmol/min/m2 at 5 months, 942 (565–1,240) pmol/min/m2 at 12 months (P = 0.028 from baseline), and 936 (635–1,435) pmol/min/m2 at 24 months (P = 0.023 from baseline; n = 20 of 39 of those initially in remission). This was comparable to the NDC group (1,016 [857–1,507] pmol/min/m2) by 12 (P = 0.064) and 24 (P = 0.244) months. Median first-phase insulin response increased from baseline to 5 months (42 [4–67] to 107 [59–163] pmol/min/m2; P < 0.0001) and then remained stable at 12 and 24 months (110 [59–201] and 125 [65–166] pmol/min/m2, respectively; P < 0.0001 vs. baseline) but lower than that of the NDC group (250 [226–429] pmol/min/m2; P < 0.0001).

CONCLUSIONS

A gradual increase in assessed functional β-cell capacity occurred after weight loss, becoming similar to that of NDC group participants by 12 months. This result was unchanged at 2 years with continuing remission of type 2 diabetes.




ma

Amid an Unfolding Humanitarian Crisis in Syria, the European Union Faces the Perils of Devolving Migration Management to Turkey

The high-stakes gambit taken by Turkish President Recep Tayyip Erdoğan to allow tens of thousands of asylum seekers and migrants free movement to the Greek border demonstrated the fragility of the EU-Turkey deal and the European Union's broader approach to outsource migration management to third countries. This article examines the causes for the tensions, the EU approach to external partnerships, and a hardening European attitude towards unwanted arrivals.




ma

The Future of Refugee Resettlement: Made in Europe?

Europe's refugee resettlement capacity has grown dramatically, with resettlement places more than doubling since 2014, even as European countries have become an emerging center for innovation. As Europe accounts for a rising share of resettlement worldwide, will European policymakers claim a leadership role in shaping the global resettlement agenda or fall into this position by default?




ma

As COVID-19 Slows Human Mobility, Can the Global Compact for Migration Meet the Test for a Changed Era?

The coronavirus pandemic dramatically reshaped how human mobility is managed just as the Global Compact for Safe, Orderly, and Regular Migration was beginning to move from paper to implementation. As governments face pressing public-health, economic, and other concerns in responding to COVID-19, this MPI Europe commentary explores whether the first comprehensive global agreement on migration can adjust to a changed reality.




ma

Humanitarian Protection in an Era of Pandemic

MPI and MPI Europe experts discuss the effects of the coronavirus pandemic on asylum systems in Europe and North America, as well as in developing regions, where 85 percent of refugees live. During this freeform conversation, our analysts also assess the implications for the principle of asylum and the future for a post-World War II humanitarian protection system that is under threat.




ma

“Cubicle Activism”: Companies Face Growing Demands from Workers to Cut Ties with ICE and Others in Immigration Arena

From online petitions to organized walkouts, corporate America is facing increasing employee activism over its business involvement with agencies implementing the federal government's immigration policies. This "cubicle activism," seen at companies ranging from Amazon and Google to Bank of America and Wayfair, has garnered mixed success to date, forcing divestiture from private prison contractors but fewer results in other contexts, as this article explores.




ma

Strategic Solutions for the United States and Mexico to Manage the Migration Crisis

Amid surging migration from Central America, the United States and Mexico in June 2019 agreed to a series of enforcement measures. Yet these near-term efforts will be difficult to maintain given chronic institutional weaknesses and poorly thought-out policy structures in both countries. This commentary, by the presidents of MPI and El Colegio de México, offers a set of long-term, collaborative solutions to dissuade illegal migration while ensuring fairness to those seeking protection.




ma

Dr. Loree Bolin is ADA’s 2020 Humanitarian Award recipient

Dr. Loree Bolin’s humanitarian work has drawn accolades from the dental community in her home state of Washington, and now Dr. Bolin is being recognized nationally by being named the recipient of the ADA’s 2020 Humanitarian Award, bestowed by the ADA Board of Trustees.